Retacrit®, Biosimilar of Epoetin Alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation.

Laribi, Kamel; Spaeth, Dominique; Scotte, Florian; Ray-Coquard, Isabelle

Laribi, Kamel; Spaeth, Dominique; Scotte, Florian; Ray-Coquard, Isabelle.

Affiliation

Laribi K; Service d'Hématologie, Centre Hospitalier, Le Mans, France.
Spaeth D; Service d'Oncologie, Polyclinique de Gentilly, Nancy, France.
Scotte F; Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.
Ray-Coquard I; Service d'Oncologie, Centre Léon Bérard, Laboratoire RESHAPE U1290, Université Claude Bernard Lyon Est, Lyon, France.

Oncology ; 100(10): 519-528, 2022.

Article in En | MEDLINE | ID: mdl-35051930

Subject(s)

Anemia; Antineoplastic Agents; Biosimilar Pharmaceuticals; Hematinics; Neoplasms; Aged; Anemia/chemically induced; Antineoplastic Agents/adverse effects; Biosimilar Pharmaceuticals/adverse effects; Dietary Supplements; Epoetin Alfa/therapeutic use; Female; Ferritins/adverse effects; Hematinics/adverse effects; Humans; Iron; Neoplasms/drug therapy; Prospective Studies; Recombinant Proteins/adverse effects; Transferrins/therapeutic use

Key words

Biosimilars; Chemotherapy-induced anemia; Epoetin alfa; Iron supplementation

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biosimilar Pharmaceuticals / Hematinics / Anemia / Neoplasms / Antineoplastic Agents Type of study: Observational_studies Limits: Aged / Female / Humans Language: En Journal: Oncology Year: 2022 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google